Group One Trading
OBX icon

Group One Trading’s Obsidian Therapeutics OBX Stock Holding History

Group One Trading’s Portfolio OBX Stock Details OBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$357 Buy
+26
New +$508 ﹤0.01% 7301

Other funds holding OBX

Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Revelation Capital Management
Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Group One Trading's OBX Position: Q3 2026 in Review

Group One Trading opened a new position in Obsidian Therapeutics (OBX) in Q3 2026: 26 shares worth $357. The stake represents ﹤0.01% of the portfolio and ranks #7301 among its holdings.

11 funds tracked by Wall St. Rank hold OBX as of Q3 2026.

  • Group One Trading held 26 shares of Obsidian Therapeutics worth $357 as of Q3 2026.
  • Obsidian Therapeutics was a new Group One Trading position in Q3 2026.
  • Obsidian Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #7301 holding.
  • 11 funds tracked by Wall St. Rank held Obsidian Therapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.